GlaxoSmithKline submits UMEC/VI for approval in EU

Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD).

Pharmaceutical companies GlaxoSmithKline (GSK) and Theravance have submitted a regulatory application in the EU for UMEC/VI medicine, a product used to treat chronic obstructive pulmonary disease (COPD).

The companies previously announced the submission of a regulatory application in the US on December 18th.

The firms also plan to make submissions for regulatory approval for UMEC monotherapy later this year.

Subscribe to MoneyWeek

Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Get 6 issues free
https://cdn.mos.cms.futurecdn.net/flexiimages/mw70aro6gl1676370748.jpg

Sign up to Money Morning

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter

Sign up

Glaxo's share price rose 0.44% to 1,379.50p by 13:22.

NR